Medpal AI PLC - Half-year Financial Report
MedPal AI plc
("MedPal AI" or the "Company")
Interim Results for the six months ended
MedPal AI (AIM: MPAL, FRA: Z1N), announces its interim results for the period ended
Chief Executive Officer's Statement
I am delighted to present MedPal AI plc's first interim results as an AIM-quoted company, covering the six months to
At Admission, MedPal AI was a pre-revenue digital health business built around the MedPal app - an AI-powered consumer platform aggregating data from more than 100 wearables and health apps into a unified user profile. Our admission document set out a strategy of growing the app through direct-to-consumer, corporate wellness and B2B channels, and contemplated acquisitions of complementary businesses in the healthcare sphere, including online pharmacies and telehealth, that would operate alongside and interact with the MedPal app to provide users with extended functionality and a seamless service. The six months under review have seen us execute that strategy at pace.
The MedPal app remains the core of the Company and the front door through which consumers access our platform. During the period we have added an NHS-contracted pharmacy operation, a private GLP-1 weight-loss clinic and direct supply agreements with the world's two leading GLP-1 manufacturers. Together with the app, these complementary capabilities form what we now describe as the MedPal Health OS: a single, vertically integrated platform delivering personalised, AI-driven health support, with the MedPal app as the consumer interface.
The financial results of that execution represent a step change. From a pre-revenue position at admission, the Company has delivered
Highlights
Financial highlights
• First revenues delivered:
• Gross profit of
• Annualised pharmacy revenue run rate of over
• Loss for the period of
• Equity capital raised of
Strategic and operational highlights
• Universal Pharmacy acquisition announced on
• Direct supply agreement with Eli Lilly secured in
• Care
• Secondary listing on the Frankfurt Stock Exchange (FRA: Z1N) admitted in
• MedPal Health OS framework articulated, bringing together the existing MedPal app, the Group's clinical and pharmacy capabilities, and AI triage running on Google's Vertex AI into a single, closed-loop platform consistent with the integrated user experience contemplated at the time of Admission.
• Dispensing volumes accelerated every month, from zero items in
Trading and operational review
MedPal.clinic and the GLP-1 opportunity
Alongside the NHS pharmacy operation we have established MedPal.clinic, our private GLP-1 weight-loss clinic, operating in the same regulatory and operational framework as the broader pharmacy business. With direct supply relationships now in place with both Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy) - the only two manufacturers of the market-leading GLP-1 medicines - we are uniquely positioned in the
The MedPal app and the Health OS
The MedPal app - the foundation product on which the Company was admitted to AIM - remains at the centre of the platform and continues to evolve. The app aggregates data from more than 100 wearables and health apps into a unified user profile, as described in the Admission Document. During the period, we have continued to invest in the underlying technology, with clinical-grade AI triage now running on Google's Vertex AI.
What we now describe as the MedPal Health OS is the framework that connects the app to the complementary capabilities. Data from the app informs clinical triage; triage routes the user to the right care pathway; where prescriptions are appropriate, they are filled through our own automated pharmacy infrastructure; and the resulting physiological data is fed back into the user's profile. The Board believes the MedPal app and Health OS, together providing an integrated, seamless user experience, represent the Group's most strategically valuable assets.
Care home pharmacy supply
Our B2B care home pharmacy supply business, anchored by the contract with Care UK and serving more than 100 care homes nationally, continues to grow as a stable, high-retention revenue channel. It also provides the operational template for further care home partnerships.
Financial review
Revenue for the six months ended
During the period, the Group raised gross proceeds of
Post balance sheet events
The post-period has been every bit as active as the reporting period itself, with three landmark transactions and a refresh of the Board's composition:
•
•
• Remedi (
• Board changes: on
Outlook
MedPal AI enters the second half of the financial year with a strong operational, commercial and financial platform. We operate two GPhC-registered, automated NHS dispensing hubs, Swaffham and
Looking ahead, we expect continued strong growth in NHS dispensing volumes through the Distance Selling Pharmacy model, accelerating private GLP-1 revenues through MedPal.clinic, deeper penetration of the care home channel, and increasing engagement with the MedPal app and Health OS as the consumer platform rolls out at scale. We have a number of material commercial conversations in progress, all of which sit within the strategic framework set out at the time of Admission, and we look forward to updating shareholders in due course.
I would like to thank our shareholders, our advisers and, above all, the rapidly growing MedPal team for their continued support and disciplined execution. The first six months as a listed company have moved MedPal AI from start-up to scale-up. The next six are about converting that platform into sustained, profitable growth.
Founder and Chief Executive Officer
|
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 6 MONTHS ENDED
|
|
6 months ended |
6 months ended |
|
|
|
Unaudited |
Unaudited |
|
|
Note |
£ |
£ |
|
Continuing operations |
|
|
|
|
|
|
|
|
|
Revenue |
|
1,603,943 |
- |
|
Cost of sales |
|
(1,235,393) |
- |
|
Gross Profit |
|
368,550 |
- |
|
|
|
|
|
|
Administrative costs |
3 |
(3,360,434) |
(175,576) |
|
Development costs |
|
(378,139) |
- |
|
Depreciation & amortisation |
|
(57,879) |
- |
|
Operating loss |
|
(3,427,902) |
(175,576) |
|
|
|
|
|
|
Interest expense |
|
(32,728) |
- |
|
Interest income |
|
3,316 |
- |
|
Loss before tax from continuing operations |
|
(3,457,314) |
(175,576) |
|
|
|
|
|
|
Taxation on profit on ordinary activities |
|
183,184 |
- |
|
Loss for the period from continuing operations |
|
(3,274,130) |
(175,576) |
|
Other comprehensive income |
|
- |
- |
|
Total comprehensive loss for the period attributable to shareholders from continuing operations |
|
(3,274,130) |
(175,576) |
|
|
|
|
|
|
Basic and dilutive earnings per share - pence |
4 |
(0.77) |
(0.380) |
|
|
|
|
|
The accompanying notes form an integral part of the Financial Information.
|
STATEMENT OF FINANCIAL POSITION AS AT
|
|
As at |
As at |
|
|
|
Unaudited |
Audited |
|
|
Note |
£ |
£ |
|
NON-CURRENT ASSETS |
|
|
|
|
Right of Use Asset |
|
412,953 |
- |
|
Property, plant & equipment |
|
139,944 |
- |
|
Intangibles |
5 |
287,626 |
257,318 |
|
TOTAL NON-CURRENT ASSETS |
|
840,523 |
257,318 |
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
Inventory |
|
215,408 |
- |
|
Other current assets |
|
969,148 |
- |
|
Trade receivables |
|
292,566 |
254,751 |
|
Cash and cash equivalents |
|
4,189 |
1,537,124 |
|
TOTAL CURRENT ASSETS |
|
1,481,311 |
1,791,875 |
|
TOTAL ASSETS |
|
2,321,834 |
2,049,193 |
|
|
|
|
|
|
EQUITY |
|
|
|
|
Share capital |
7 |
91,030 |
82,616 |
|
Share premium |
7 |
4,279,412 |
1,957,900 |
|
Share-based payments reserve |
8 |
3,485,780 |
3,433,078 |
|
Retained earnings |
|
(7,341,268) |
(4,084,843) |
|
TOTAL EQUITY |
|
514,954 |
1,388,751 |
|
NON-CURRENT LIABILITIES |
|
|
|
|
Right of use liability-Non current |
|
377,692 |
- |
|
CURRENT LIABILITIES |
|
|
|
|
Right of use liability |
|
64,304 |
- |
|
Borrowings |
|
302,408 |
- |
|
Trade and other payables |
|
1,062,476 |
660,442 |
|
TOTAL CURRENT LIABILITIES |
|
1,429,188 |
660,442 |
|
TOTAL LIABILITIES |
|
1,806,880 |
660,442 |
|
TOTAL EQUITY AND LIABILITIES |
|
2,321,834 |
2,049,193 |
The accompanying notes form an integral part of the Financial Information
|
STATEMENT OF CHANGES IN EQUITY AS AT
|
Share capital |
Share premium |
Share based payments reserve |
Retained earnings |
Total equity |
|
|
£ |
£ |
£ |
£ |
£ |
|
Balance at |
4,620 |
66,330 |
- |
(82,931) |
(11,981) |
|
Loss for the year |
- |
- |
- |
(4,001,912) |
(4,001,912) |
|
Total comprehensive income for the year |
- |
- |
- |
(4,001,912) |
(4,001,912) |
|
Transactions with owners in own capacity |
|
|
|
|
|
|
Ordinary Shares issued in the year |
77,996 |
3,135,694 |
- |
- |
3,213,690 |
|
Share issue costs |
- |
(1,244,124) |
- |
- |
(1,244,124) |
|
Warrants and options issued in the current year |
- |
- |
3,433,078 |
|
3,433,078 |
|
Transactions with owners in own capacity |
77,996 |
1,891,570 |
3,433,078 |
- |
5,402,644 |
|
Balance at |
82,616 |
1,957,900 |
3,433,078 |
(4,084,843) |
1,388,751 |
|
Loss for the period |
- |
- |
- |
(3,274,130) |
(3,274,130) |
|
Total comprehensive income for the period |
- |
- |
- |
(3,274,130) |
(3,274,130) |
|
Transactions with owners in own capacity |
|
|
|
|
|
|
Ordinary Shares issued in the period |
8,414 |
2,529,990 |
- |
- |
2,538,404 |
|
Share issue costs |
- |
(208,478) |
- |
- |
(208,478) |
|
Warrants and options issued in the current period |
- |
- |
70,405 |
- |
70,405 |
|
Warrants and options cancelled during the current period |
- |
- |
(17,705) |
17,705 |
- |
|
Transactions with owners in own capacity |
8,414 |
2,321,512 |
52,700 |
17,705 |
2,400,331 |
|
Balance at |
91,030 |
4,279,412 |
3,485,778 |
(7,341,268) |
514,952 |
The accompanying notes form an integral part of the Financial Information.
|
STATEMENT OF CASH FLOWS AS AT
|
|
6 month period ended 28 February 2026 |
6 month period ended 28 February 2025 |
|
|
Notes |
£ |
£ |
|
Cash flow from operating activities |
|
|
|
|
Loss for the period |
|
(3,274,130) |
(175,576) |
|
Adjustments for: |
|
|
|
|
Depreciation & Amortisation |
|
57,879 |
- |
|
Interest |
|
10,360 |
- |
|
Share based payments |
|
70,407 |
- |
|
Changes in working capital: |
|
|
|
|
(Increase)/decrease in other receivables (including inventory) |
|
(955,997) |
(35,902) |
|
Increase/(decrease) in trade and other payables |
|
385,662 |
2,997 |
|
Net cash used in operating activities |
|
(3,705,819) |
(208,481) |
|
Cash flows from investing activities |
|
|
|
|
Purchase of intangible assets |
|
(56,040) |
- |
|
Purchase of property, plant and equipment |
|
(153,410) |
- |
|
Net cash used in investing activities |
|
(209,450) |
- |
|
Cash flows from financing activities |
|
|
|
|
Share capital in advance |
|
- |
320,101 |
|
Proceeds from issuance of ordinary shares |
|
2,329,926 |
- |
|
Proceeds from borrowings |
|
52,408 |
- |
|
Net cash generated from financing activities |
|
2,382,334 |
320,101 |
|
Net decrease in cash and cash equivalents |
|
(1,532,935) |
111,620 |
|
Cash and cash equivalents at beginning of period |
|
1,537,124 |
253 |
|
Cash and cash equivalents at the end of the period |
|
4,189 |
111,873 |
There was the following material non-cash movements during the period:
· Assumption of
NOTES TO THE CONDENSED INTERIM FINANCIAL INFORMATION
AS AT
General information
The Company was incorporated on
The address of its registered office is Floor 8
The Directors of the Company are responsible for the Financial Information in the interim report.
1. Accounting Policies
IAS 8 requires that management shall use its judgement in developing and applying accounting policies that result in information which is relevant to the economic decision-making needs of users, that are reliable, free from bias, prudent, complete and represent faithfully the financial position, financial performance and cash flows of the entity.
2. Basis of preparation
The Interim Financial Information has been prepared in accordance with the
The Interim Financial Information does not include all disclosures that would otherwise be required in a complete set of Financial Statements but has been prepared in accordance with the existing accounting policies of the Company.
The Interim Financial Information for the period ended
Medpal AI Plc's Interim Financial Information has been prepared using the measurement bases specified by IFRS for each type of asset, liability, income and expense.
The Interim Financial Information does not constitute statutory accounts within the meaning of section 434 of the Companies Act 2006.
The Interim Financial Information is presented in £ unless otherwise stated, which is Medpal AI's presentational currency.
2.1 Going concern
The Directors have made an assessment of the Company's ability to continue as a going concern and are satisfied that the Company has adequate resources to continue in operational existence for the foreseeable future. The Company, therefore, continues to adopt the going concern basis in preparing its Interim Financial Information.
2.2 Critical accounting estimates and judgments
In preparing the Interim Financial Information, the directors must make judgments on how to apply the Company's accounting policies and make estimates about the future. Estimates and judgements are continuously evaluated based on experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may deviate from these estimates and assumptions.
During the period it was determined that there were no key accounting estimates or judgements.
3. Administrative expenses
|
|
|
6 month period ended 28 Feb 2026 |
6 month period ended 28 Feb 2025 |
|
|
|
£ |
£ |
|
Staff costs |
|
1,547,593 |
85,000 |
|
Advertising & marketing |
|
1,070,433 |
- |
|
Premises costs |
|
195,713 |
15,000 |
|
Professional services |
|
281,738 |
41,840 |
|
Travel & entertainment |
|
42,234 |
2,333 |
|
IPO Costs |
|
(20,550) |
27,794 |
|
IT software and consumables |
|
72,388 |
2,969 |
|
Legal |
|
118,517 |
|
|
Regulatory costs |
|
46,640 |
- |
|
Other expenses |
|
5,728 |
640 |
|
|
|
3,360,434 |
175,576 |
4. Earnings per share
The calculation of the basic and diluted earnings per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period.
|
|
|
6 month period ended 28 Feb 2026 |
6 month period ended 28 Feb 2025 |
|
Loss attributable to equity holders of the Company |
|
(3,274,130) |
(175,576) |
|
Weighted number of ordinary shares in issue |
|
424,235,948 |
46,200,000 |
|
Basic & dilutive earnings per share from continuing operations - pence |
|
(0.77) |
(0.38) |
There is no difference between the diluted loss per share and the basic loss per share presented as there are no dilutive financial instruments.
5. Acquisition of Universal Pharmacy
On
The transaction has been accounted for as an asset purchase, as the assets acquired did not constitute a business for the purposes of IFRS 3. The total cost, including directly attributable transaction costs capitalised in accordance with IAS 38, has been allocated across the identifiable assets on the basis of their relative fair values at the acquisition date.
|
|
||
|
BPA consideration - NHS and DSP licence |
29,999 |
|
|
BPA consideration - plant and machinery |
15,000 |
|
|
BPA consideration - other |
1 |
|
|
Total BPA consideration |
|
45,000 |
|
|
|
|
|
Directly attributable transaction costs (legal and professional) |
|
25,646 |
|
Total cost of assets acquired |
|
70,646 |
|
|
|
|
|
Allocated to: |
|
|
|
Intangible asset - NHS and DSP licence (indefinite useful life) |
|
55,645 |
|
Plant and machinery |
|
15,000 |
|
Other fixed assets |
|
1 |
|
Total |
|
70,646 |
The initial exchange payment of
Intangible asset - NHS and DSP licence
The primary asset acquired is the NHS community pharmacy contractor registration and distance selling pharmacy (DSP) licence. The Directors have assessed this intangible asset as having an indefinite useful life on the basis that the licence is not subject to a fixed contractual term, is renewable by the Group subject to ongoing regulatory compliance, and there is no foreseeable limit to the period over which the asset is expected to generate net cash inflows for the Group.
Accordingly, the asset is not amortised. In accordance with IAS 36, it is subject to impairment testing at least annually and whenever there is an indication that it may be impaired. No impairment indicators were identified at
6. Trade and other receivables
|
|
|
28 February 2026 |
|
|
|
|
£ |
£ |
|
Prepayments |
|
487,618 |
390,743 |
|
Other current assets |
|
150,955 |
- |
|
VAT |
|
330,576 |
114,008 |
|
|
|
969,149 |
504,751 |
7. Share capital
|
|
Number of shares |
Ordinary shares |
Share premium |
Total |
|
|
Number |
£ |
£ |
£ |
|
Balance at |
46,200,000 |
4,620 |
66,330 |
70,950 |
|
Founder round 2 |
56,900,000 |
5,690 |
- |
5,690 |
|
Series A Capital Raise 3 |
43,450,000 |
4,345 |
|
434,500 |
|
Consideration 4 |
192,500,000 |
19,250 |
173,250 |
192,500 |
|
Pre IPO 5 |
5,033,334 |
503 |
150,497 |
151,000 |
|
Fee shares 6 |
2,000,000 |
200 |
19,800 |
20,000 |
|
Share consolidation 7 |
- |
34,608 |
(34,608) |
- |
|
Pre-IPO share issue 8 |
17,000,001 |
3,400 |
406,600 |
410,000 |
|
IPO raise 9 |
50,000,000 |
10,000 |
1,990,000 |
2,000,000 |
|
Share issue costs |
- |
- |
(1,244,124) |
(1,244,124) |
|
As at |
413,083,335 |
82,616 |
1,957,900 |
2,040,516 |
|
Share issue 10 |
6,816,305 |
1,363 |
543,941 |
545,304 |
|
Share issue 11 |
7,500,000 |
1,500 |
496,725 |
498,225 |
|
Share issue 12 |
6,200,000 |
1,240 |
377,630 |
378,870 |
|
Share issue 13 |
6,500,000 |
1,300 |
338,260 |
339,560 |
|
Share issue 14 |
9,000,000 |
1,800 |
465,840 |
467,640 |
|
Share issue 15 |
6,055,000 |
1,211 |
307,594 |
308,805 |
|
Share issue costs |
|
|
(208,478) |
(208,478) |
|
As at |
455,154,640 |
91,030 |
4,279,412 |
4,370,442 |
1- 700,000 shares at
2- Issue of 56,900,000 shares at nominal value for total proceeds
3- Issue of 43,450,000 shares at
4- Issue of 192,500,000 shares to founder
5- Issue of 5,033,334 shares at
6- Issue of 2,000,000 fee shares for
7- On
8- Issue of 12,000,001 and 5,000,000 shares at
9- Issue of 50,000,000 shares at
10- Issue of 6,816,305 shares at
11- Issue of 7,500,000 shares at
12- Issue of 6,200,000 shares at
13- Issue of 6,500,000 shares at
14- Issue of 9,000,000 shares at
15- Issue of 6,055,000 shares at
The share premium represents the difference between the nominal value of the shares issued and the actual amount subscribed less; the cost of issue of the shares, the value of the bonus share issue, or any bonus warrant issue.
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have a par value of
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.
All issued shares are fully paid.
8. Options and warrants
Options
|
|
|
|
|
||
|
|
Weighted average exercise price |
Number of options |
|
Weighted average exercise price |
Number of options |
|
Opening balance |
- |
40,308,331 |
|
- |
- |
|
Options issued during the year |
|
|
|
4p |
40,308,331 |
|
Options cancelled during the year |
4p |
(6,000,000) |
|
|
- |
|
Outstanding at the end of the year |
4p |
34,308,331 |
|
4p |
40,308,331 |
|
Exercisable at the end of the year |
- |
- |
|
- |
- |
Warrants
|
|
|
|
|
||
|
|
Weighted average exercise price |
Number of warrants |
|
Weighted average exercise price |
Number of warrants |
|
Opening balance |
2p |
135,746,667 |
|
- |
- |
|
Issued during the year |
- |
- |
|
2p |
135,746,667 |
|
Outstanding at the end of the year |
2p |
135,746,667 |
|
2p |
135,746,667 |
|
Exercisable at the end of the year |
4p |
60,746,667 |
|
4p |
60,746,667 |
The fair value of the services received in return for the options and warrants granted are measured by reference to the fair value of the instrument granted. The estimate of the fair value of the instrument granted is measured based on the Black-Scholes valuations model and Barrier valuations model. The weighted average time to expiry of the warrants and options is 5.51 years.
9. Related party transactions
NHS Revenue
The
10. Capital Commitments
There were no capital commitments at
11. Contingent Liabilities
There were no contingent liabilities at
12. Events subsequent to period end
Board changes
On
Equity fundraisings and issue of fee shares
On
On
On
On
Remedi acquisition
On
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic
Enquiries:
|
MedPal AI plc
|
Via Square1 Consulting |
||
|
Cairn Financial Advisers LLP
|
+44 (0) 20 7213 0880 |
||
|
+44 (0) 20 3973 3678 |
||
|
Clear Capital Markets Limited
|
+44 (0) 20 3869 6080 |
||
|
Square1 Consulting |
+44 (0) 20 7929 5599 +44 (0) 7831 381201 |
About MedPal AI
MedPal AI is a
Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages BD Rowa VMAX robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.
MedPal AI has a partnership agreement with Epassi
Forward Looking Statements
This announcement contains forward-looking statements, which are based on the Company's current expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. Forward-looking statements are often identified by words such as "believes", "expects", "intends", "may", "will", "should", "could", "plans", "targets", "aims" or similar expressions. Such statements are subject to risks, assumptions and uncertainties and actual results, performance or events may differ materially from those expressed or implied by them. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law, the AIM Rules for Companies, the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE